Home > Maligne hematologie > Myeloïde ziekten > Myelodysplastisch syndroom > CMBG453B12301

CMBG453B12301

A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 29-5-2024, 1:59